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Abstract
Carbohydrate antigen 72-4 (CA72-4) is an important biomarker associated closely with diagnosis and
prognosis of early gastric cancer. How to realize quick, sensitive, specific, and quantitative detection of CA72-4
in clinical specimens has become a great requirement. Herein, we reported a CdSe/ZnS quantum dot-labeled
lateral flow test strip combined with a charge-coupled device (CCD)-based reader was developed for rapid,
sensitive, and quantitative detection of CA72-4. Two mouse monoclonal antibodies (mAbs) against CA72-4
were employed. One of them was coated as a test line, while another mAb was labeled with quantum dots
and coated onto conjugate pad. The goat anti-mouse IgG was immobilized as a control line. After sample
was added, a sandwich structure was formed with CA72-4 and these two mAbs. The fluorescent signal from
quantum dots (QD)-labeled mAb in sandwich structure was related to the amount of detected CA72-4. A
CCD-based reader was used to realize quantitative detection of CA72-4. Results showed that developed
QD-labeled lateral flow strips to detect CA72-4 biomarker with the sensitivity of 2 IU/mL and 10 min detection time.
One hundred sera samples from clinical patients with gastric cancer and healthy people were used to confirm
specificity of this strip method; results showed that established strip method own 100 % reproducibility and 100 %
specificity compared with Roche electrochemiluminescence assay results. In conclusion, CdSe/ZnS quantum
dot-labeled lateral flow strips for detection of CA72-4 could realize rapid, sensitive, and specific detection of
clinical samples and could own great potential in clinical translation in near future.
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Background
Stomach cancer is the fourth most common cancer and
the second leading cause of cancer-related death world-
wide [1–3]. It ranks number two among all malignant
tumors in China according to the latest cancer disease
spectrum [4]. The gastric cancer prognosis is very poor
with 5-year survivals below 24 % [5, 6]. Therefore, it is
urgent to find an early diagnostic tool to increase the
gastric cancer survival rate.
Up to date, clinical biomarkers for diagnosis of early
gastric cancer are still very few. For example, so far car-
cinoembryonic antigen (CEA) is often used to screen
out or diagnose early gastric cancer patients in the hos-
pital [7, 8]; nevertheless, due to the low sensitivity and
specificity, CEA examination cannot screen out most
early gastric cancer patients, therefore, to look for new
biomarkers associated with gastric cancer diagnosis is an
important task. In recent years, gastric cancer-related
carbohydrate antigen 72-4 (CA72-4) has been shown a
higher sensitivity in early gastric cancer or recurrent
cases than CEA, particularly the specificity of CA72-4
reached to 97 % in 58 disease-free objects (56 out of 58
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were undetected) [9]. These reports highly suggested
that CA72-4 may be considered as a specific biomarker
of gastric cancer. In the different stages of gastric cancer,
CA72-4 antigen was released into the blood circulation
system and leaded to different levels in sera samples [10,
11]. Studies correlating levels of CA72-4 with findings of
pathologic exams in gastric cancer have shown signifi-
cantly higher levels associated with gastric serosal inva-
sion caused by gastric cancer, lymph nodal metastases,
and invasion of veins or lymphatic vessels into the gas-
tric wall [12–15]. All these studies suggested that levels
of CA72-4 in the sera could efficiently predict different
stages of gastric cancer. Therefore, in this study, we se-
lected CA72-4 antigen as our detection target molecule.
Immunochromatographic test strip (ICTS) has
been widely used in qualitative and semi-quantitative
detection of biomarkers. This technology uses antigen-
antibody reaction features to detect numbers of analytes,
including antigens, antibodies, and even the yields of nu-
cleic acid amplification tests [16–19]. This technology has
the advantages such as user-friendly format, rapid detec-
tion, long-term stability, and relatively low cost. Trad-
itional colloidal gold lateral flow tests are analyzed by
naked eyes, which is subjective and inaccurate. For these
reasons, several groups developed electrochemical immu-
nosensor and CdSe or CdTe quantum dot-labeled lateral
flow strips combined with charge-coupled device (CCD)-
based reader for ultrasensitive quantitative detection of
antibody or antigen in Shanghai Jiao Tong University
[20, 21]. Although CdTe and CdSe exhibited strong
fluorescent signals, as the used time was extended for
more than 6 months, the prepared quantum dot
(QD)-labeled lateral flow strips displayed decreased
fluorescent signals in the course of clinical sample
examination; how to keep the stable fluorescent
signals in prepared QD-labeled lateral flow strips has
become a challenge.
In this study, CdSe/ZnS quantum dots were selected
and labeled with anti-CA72-4 monoclonal antibody. A
new type of stable flow strips were developed to quantify
the CA72-4 antigen combined with the previous in-
house-developed CCD-based reader. In order to exam
the detection sensitivity, specificity, speed, and repeat-
ability of the prepared lateral flow strips, 100 specimens
were collected and results have been compared with the
results of Roche electroluminescent assays.
Methods
Chemicals and Materials
Water-soluble CdSe/ZnS quantum dots (excitation and
emission wavelengths were 365 and 620 nm, respect-
ively) were obtained from Najing Technology Co. Ltd.
(China) (Fig. 1a).The QDs were with carboxyl groups on
their surface and were 5–7 nm in diameter. CA72-4 is
commonly detected through monoclonal antibody CC49
and B72.3 [22–24]. B72.3 and CC49 were purchased
from Shanghai Cnpair Biotech Co. Ltd. (China). Goat
anti-mouse IgG polyclonal antibody and CA72-4 antigen
were also provided by Shanghai Cnpair Biotech Co. Ltd.
(China). Bovine serum albumin (BSA) was obtained
from Sigma-Aldrich (USA). 1-Ethyl-3-(3-dimethylami-
nopropyl) carbodiimide hydrochloride (EDC), 2-(N-
morpholino) ethanesulfonic acid (MES) and N-hydro-
xysuccinimide (NHS) were from Shanghai Aladdin
Industrial Corporation (China). Other chemicals (ana-
lytical grade) were obtained from Sigma Company.
PALL Vivid170 Nitrocellulose (NC), Bilbulous paper,
semirigid polyvinylchloride (PVC) sheets, glass fiber
using for conjugate pad, sample pad, and adsorbent
pad were all supplied by Shanghai JieYi Biotechnology
Co., Ltd. (China). Fluorescence spectrophotometer
was purchased from Hitachi High-Technologies.
Clinic Samples
This study was approved by the Medical Ethics Commit-
tee of Zhujiang Hospital. Informed consent was obtained
from patients. Human experimentation guidelines of the
Zhujiang Hospital were followed in the conduct of
clinical research. In this study, we selected 70 CA72-4-
positive serum samples from gastric cancer patients
collected at the Out-Patient Department, Zhujiang
Hospital, during October 2013 to August 2015. The
negative control group consisted of 30 healthy CA
72-4-negative sera from volunteer blood donors. All
samples were collected and kept at −70 °C refrigerator for
further use.
Preparation of CA72-4 mAb Labeled With CdSe/ZnS QDs
The CdSe/ZnS quantum dots were obtained from
Najing Technology Co. Ltd. (China), and characterized by
UNICAM UV 300 Spectrophotometer (Thermo Spectro-
nic, USA), high-resolution transmission electron micro-
scope (TEM), and PerkinElmer LS 55 Spectrofluorimeter.
For conjugation of CA72-4 mAb with CdSe/ZnS quantum
dots with carboxyl group (Fig. 1a), all steps were protected
from light to avoid fluorescent quenching of QDs. In brief,
QDs was sequentially pretreated with EDC and NHS.
Then, QDs and EDC in 1:4000 (mol/mol) were added to
0.01 M MES (pH = 6.0) with continuous gentle vortex
mixture for 15 min. NHS (QDs: NHS was 1:2000, mol/
mol) was added after wash with 0.02 M PBS (pH = 7.2)
and further incubated for 15 min. Next, the pretreated
QDs were mixed with anti-CA72-4 mAb, CC49, in 1:8
(mol/mol), following with incubation in room temperature
for 3 h and 17 °C overnight. Finally, QD-conjugated CC49
was blocked using 1.5 % BSA in PBS for 30 min after
wash by centrifugation. The efficient of conjugation
was checked though BCA protein assay kit (Beyotime
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Biotechnology, China) and running of 50 % agarose
gel in 80 V, 220 mA for 40 min. In addition, the
shape of QDs after conjugation was observed through
TEM.
Preparation of Lateral Flow Test Strips
The lateral flow test strip was composed of sample
pad, conjugate pad, NC membrane, and absorbent
pad, and all parts were pasted on a PVC baking
(Fig. 1b). The sample pad was saturated with PBS
containing 0.1 % Tween-20 (v/v) and dried at room
temperature. The prepared QD-labeled anti-CA72-4
mAb (CC49) was applied into the conjugate pad,
dried at 37 °C overnight and stored at 4 °C. To pre-
pare the test line and control line, Biodot BJQ 3000
model XYZ 3200 was used. A solution of anti-CA72-
4 mAb (B72.3, 2 mg/mL) was immobilized on NC
membrane as a test line. The goat anti-mouse IgG
was immobilized at a concentration of 1 mg/mL as a
control line. After immobilization, the NC membrane
was dried at 37 °C for 1 h and then blocked with
PBS containing 1 % BSA (w/v). Absorbent pad was
not treated. The sample pad, conjugate pad, coated
membrane, and absorbent pad were sequentially
laminated and pasted to a PVC backing pad with
proper overlaps to ensure that the testing solution
could migrate through the whole test strip. Then, the
whole assembled strip was cut lengthways into strips
with 3 mm width and stored in sealed plastic tubes
until use.
Selection of CCD-Based Lateral Test Strip Reader
The lateral test strip reader is a very key tool for quanti-
tative detection of CA72-4. In previous reports, our
group has developed a CCD-based reader to detect QD
fluorescent signals quantitatively [21]. In this study, we
chose this portable fluorescence immunoassay chip de-
tector as the test strip reader. In addition, a UV laser
was used to directly observe the fluorescence on the
lateral flow test strips.
Assay Procedure
To perform the fluorescence assay, the prepared
QD-based ICTS was put on a clean horizontal plat-
form, and a desired volume of the standard antigen
CA72-4 was dropped into the sample pad and migrated
towards the other end of the strip under capillary action
(Fig. 1c). PBS without CA72-4 was used as control. Each
sample test was repeated for three times under the same
condition. After immune reaction for 10 min, the test strip
was placed into the tests strip reader, followed by record-
ing fluorescence intensity of test line and control line. Fur-
ther, 70 serum samples from CA72-4-positive patients and
30 serum samples from CA72-4-negative healthy volun-
teers were detected. All the serum samples were deter-
mined with electrochemiluminescence assay kit of Roche.
Data Analysis
All data are presented in this paper as means ± SD.
Standard curve was produced from GraphPad Prism 5
(GraphPad Software, San Diego, USA). Data was also
Fig. 1 Schematic diagram of QD-based ICTS. a Conjugation of CdSe/ZnS QDs with CA72-4 mAb (CC49). b Structure of QD-based ICTS.
c Sample containing CA72-4 was dropped to sample pad and migrated along the ICTS. Firstly, CA72-4 in the samples combined with
QDs probeat conjugate pad. The formed complexes continued to migrate along the membrane and were captured by B72.3 on test
line and formed QD-labeled CC49-CA72-4–B72.3 complexes. As the liquid sample continued migrating, the residual CC49 was captured
by the goat anti-mouse IgG immobilized on control line. The excess QD conjugates continued to migrate towards the absorbent pad
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analyzed using GraphPad Prism 5; statistical differences
were evaluated using the t test and considered signifi-
cance at P < 0.05 level. Roche electroluminescent assay is
considered as a golden standard method to detect gastric
cancer CA72-4 antigen. X2 was employed to get sensitiv-
ity and specificity compared with the golden standard
method.
Results and Discussion
Characterizations of QDs and Anti-CA72-4 mAb Labeled
With QDs
Water-soluble CdSe/ZnS quantum dots (excitation and
emission wavelengths were 365 and 620 nm, respect-
ively) were purchased from commercialization company.
The QDs were modified with carboxyl groups on their
surface and were 5–7 nm in diameter. The QDs had a
good dispersion as shown in Fig. 2a. QDs were emitted
under the laser at a wavelength of 620 nm. Under the
365-nm UV light excitation, the images in Fig. 2b
showed the relative photo luminescence intensity and
fluorescence image of QDs. To improve the sensitivity of
detecting mAb, CC49 was conjugated with QDs as
probes. To evaluate the efficiency of conjugation of QD-
labeled CC49, QD-labeled CC49 were loaded in a 50 %
agarose gel firstly. The different fluorescence bands were
observed under the UV light after the electrophoresis.
CC49 (160 kDa) labeled with QDs shows 890 kDa. The
QD-labeled CC49 presents a larger molecular weight
and ran slower than naked QDs (Fig. 3a). In order to an-
ticipate the ration of conjugation, BCA protein assay kit
was used to detect the unlabeled CC49 in the super-
natants. After centrifugation, the QD-labeled CC49
was in the bottom of centrifugation tubes. A formula was
generated using protein standards (y = 0.1382x − 0.0016,
R = 0.998) (Fig. 3b). The unlabeled antibody in the
supernatant, after separating QD-labeled CC49 with
centrifugation, was collected. We then quantify both
the total CC49 and unlabeled CC49 with BCA assay.
The QD-labeled CC49 was calculated via the total
antibody minus the unlabeled antibody. The ratio
between QD-labeled CC49 and total CC49 has been
counted as 17.85 ± 4.501 % (mean ± SD, n = 10). Since
CC49 and QDs used for conjugation were 8:1 (mol/mol),
the real conjugation efficiency of CC49 and QDs was dra-
matically high. We finally used TEM to observe the shape
change after conjugating CC49 with QDs. We found that
the QD-labeled CC49 formed loose and larger parti-
cles (Fig.3c, right), while naked QDs particles were smaller
in size and deep in color (Fig. 3c, left). Taken together, an
effective conjugation of QDs with anti-CA72-4 mAb was
well performed in this study.
Emission and Excitation of QDs Probe
Although we have gotten an efficient conjugation of
QDs and CC49, an anti-CA72-4 mAb, whether the
emission and excitation of QD-labeled CC49 were
same as naked QDs remains unknown. Naked QDs
and QD-labeled CC49 were excited at 365 nm. To
determine the characterization of excitation of the
QD-labeled CC49, we firstly used a continuous range
of excitation light from 200 to 600 nm to check the
characterization of excitation light for QD-labeled
CC49. Absorbance of samples was detected. The QD-
labeled CC49 showed a similar manner with naked
QDs, which excited at 200 to 400 nm (Fig. 4a). We
then observed the emission with a UV laser. Both
QDs and QD-labeled CC49 showed bright emitted
lights (Fig. 4b). Moreover, emitted lights were also
measured with spectrophotometer. QD-labeled CC49
exhibited the strong fluorescence signal and narrow
emission spectra as naked QDs, which presented an
emission peak at 620 nm (Fig. 4c). Moreover, QD-
labeled CC49 also showed a distinctive small absorb-
ance peak around 280 nm, as a characterization of
proteins, indicating that antibody was included. In all,
our QD-labeled CC49 has the emitting and exciting
features coming from both monoclonal antibody and
QDs, suggesting this QD-labeled CC49 is appropriate
for detection of CA72-4.
Fig. 2 Characterizations of QDs. a TEM of QDs. b Exciting of QDs in UV light
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Fig. 3 Conjugation of QDs with CC49. a Naked QDs and QD-labeled CC49 were run on a 50 % agarose gel. b Standard curve for detecting
unlabeled CC49 in the supernatant of conjugation through a BCA protein assay kit. c TEM of naked QDs and QD-labeled CC49. The results of
three independent experiments showing a similar trend are depicted
Fig. 4 Emission and excitation of QD-labeled CC49. a Naked QDs and QD-labeled CC49 were excited from 200 to 400 nm. A distinctive small
absorbance peak around 280 nm was observed on the QD-labeled CC49. b Naked QDs and QD-labeled CC49 were excited at 365 nm. Emission
was observed with a UV laser. c The emission peaks of QDs and QD-labeled CC49 were formed at 620 nm. The results of three independent
experiments showing a similar trend are depicted
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Detection of CA72-4 Using QD-Based ICTS
As the ICTS was successfully fabricated through effi-
ciently conjugating QDs and an anti-CA72-4 mAb,
CC49, we proposed to use it to detect CA72-4. A pur-
chased CA72-4 antigen was firstly employed. Samples
were dropped to ICTS, and 10 min later, the fluores-
cence emitted from test line, coated CA72-4 mAb
(B72.3), and control line, coated with goat anti-mouse
IgG, on ICTS were observed in UV light. We found a
dose-dependent increase of the intensity of fluorescence
following with the concentrations of CA72-4 in series
dilution (from PBS as control, 2, 5, 12.5, 25, 50, and
100 IU/mL), which also showed the lower limit to
5 IU/mL (Fig. 5a). To get a quantitative data of
CA72-4, furthermore, the portable fluorescence im-
munoassay chip detector was used. Series diluted
CA72-4 (from PBS as control, 2, 5, 12.5, 25, 50, and
100 IU/mL) were measured and provided a standard
curve (y = 67.431x − 24.753, R = 0.973) (Fig. 5b). Not-
ably, our QD-based ICTS showed extreme sensitivity
by using the portable fluorescence immunoassay chip
detector (lower limit reached to 2 IU/mL) (Fig. 5b).
We also kept and prepared ICTS in the 4 °C for 1 year
and examined the fluorescent signals by using CCD-
based reader one time per week. Results showed that no
fluorescent signal intensity difference was detected dur-
ing the period of 1 year (P > 0.05), which fully suggest
that CdSe/ZnS quantum dot-labeled anti-CA72-4 mAb
had stable fluorescent signal, and had good repeatability,
was better than other QDs such as CdTe or CdSe QDs.
Clinical Sample Test
The QD-based ICTS was used to test 100 clinical
samples. Sera from CA72-4-negative or CA72-4-positive
patients, which had been determined with electrochemilu-
minescence assay, were used to evaluate our QD-based
ICTS. A dramatic fluorescent band in test line and control
line were observed in the CA72-4-positive samples rather
than in CA72-4-negative samples (Fig. 5c). Since, CA72-4,
only higher than 6 IU/mL in the blood from patients, is
suggested to be significance for diagnosis, our ICTS was
capable for clinical application. Therefore, we used serum
samples from 70 CA72-4-positive and 30 CA72-4-
negative patients. The specificity and sensitivity of this
QD-based ICTS were determined. The QD-based ICTS
presented a perfect reproducibility compared with the
assay results from Roche (Table 1). One hundred percent
sensitivity and 100 % specificity were found in detection of
Fig. 5 Detection of CA72-4 with QD-based ICTS. a Detection of purchased CA72-4 (5 IU/mL) by a UV laser. b Detection of CA72-4-negative and
CA72-4-positive serum from patients by a UV laser. c Standard curve for detecting CA72-4 through data from a portable fluorescence immunoassay
chip detector
Table 1 Detection of results of CA72-4 in serum samples using QD-based ICTS
Serum samples ICTS Validity (95 % CI)
Positive Negative Total
Roche assay positive (n = 70) 70 0 70 Sensitivity 100 % (91–100)
Roche assay negative (n = 30) 0 30 30 Sensitivity 100 % (91–100)
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patient and healthy volunteer serum samples. The devel-
oped QD-based ICTS own obvious advantages such as
sensitive, rapid, specific, and quantitative assay.
Regarding the diagnosis of gastric cancer, imaging, and
endoscopic examinations usually play important roles
[25, 26]. However, these examinations are complex and
expensive. Detecting tumor biomarkers, such as CEA
and CA72-4, has been considered as a rapid and simple
method for screening and diagnosis of early gastric can-
cer [27]. CA72-4 has a higher sensitivity to distinguish
gastric cancer patients and disease-free healthy popula-
tion than other markers, such as CEA [9]. Therefore, in
this work, ICTS based on QD-labeled mAb for CA72-4
detection were developed. The QD-based ICTS was not
only rapid, low cost, and easy in handle but also ex-
tremely sensitive and quantitative. Nevertheless, it has
also been suggested that the sensitivity is not entirely de-
sirable in cancer detection by using a single marker [9].
Some researchers have shown that combining the CA72-
4 with other markers, such as CEA, CA199, and CA125,
could dramatically improve the sensitivity [28–30]. Our
strategy also can be easily altered to detect these mole-
cules. Anyhow, QD-based ICTS is a powerful tool in
detection of targets and can be applied potentially in
screening clinical gastric cancer patients.
Conclusions
To develop a convenient and sensitive strategy for de-
tection of CA72-4, the gastric cancer marker, in this
study, we conjugated the anti-CA72-4 mAb with
QDs, which provided a fluorescence signal for recog-
nition. Then, we constructed an ICTS by using the
QD-labeled mAb and another unlabeled mAb, which
used for capture of CA72-4. This ICTS is simple in
operation and gets sensitive quantitative results,
which had reached to 2 IU/mL. One hundred percent
sensitivity and 100 % specificity were found in detec-
tion of patients serum samples, comparing to the
electrochemiluminescence assay from Roche. In our
QD-based ICTS system, the same strategy can be
used for development of strip for several markers,
which may improve the sensitivity of diagnosis. It is
the first time, to our knowledge, to use QD-based
ICTS to detect CA72-4. This ICTS is potentially be
used as a clinical diagnostic reagent for gastric cancer,
which may help forecast tumor progression and benefit
following therapy.
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